David Naor

This inventor holds 7 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Yeda Research and Develpment & Co. Ltd. Active years: 1998-2023.

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 42.9

EPO Patents = 1

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 39(Granted Patents)

Location History:

Jerusalem, IL (1998 - 2012)
Tel Aviv, IL (2020 - 2023)

Company Filing History:

7 out of 911

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

1 out of 1,168

Yeda Research and Develpment & Co. Ltd

patents

where one patent can have more than one assignee

Years Active: 1998-2023

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11560417 - Isolated polypeptides of CD44 and uses thereof (2023-01-24),

2. 10611819 - Isolated polypeptides of CD44 and uses thereof (2020-04-07),

3. 8193311 - CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases (2012-06-05),

4. 7901909 - CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases (2011-03-08),

5. 7883857 - CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases (2011-02-08),

6. 7534605 - CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases (2009-05-19),

7. 5776970 - Tryptophan derivatives as protein tyrosine kinase blockers and their use (1998-07-07),

Title: The Innovative Contributions of David Naor

Introduction

David Naor is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of biotechnology, particularly through his work on polypeptides and their applications in treating inflammatory diseases. With a total of seven patents to his name, Naor's innovations have the potential to impact medical treatments significantly.

Latest Patents

Among his latest patents, Naor has developed isolated polypeptides of CD44, which are crucial for various therapeutic applications. These isolated polypeptides consist of specific amino acid sequences that have been identified for their anti-inflammatory properties. Additionally, he has created end-capping modified polypeptides that enhance the therapeutic efficacy of these compounds. His work includes the formulation of compositions of matter, fusion proteins, and pharmaceutical compositions aimed at treating inflammatory diseases.

Career Highlights

David Naor has had a distinguished career, working with notable organizations such as Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and Yeda Research and Development Co. Ltd. His experience in these institutions has allowed him to advance his research and contribute to the scientific community effectively.

Collaborations

Throughout his career, Naor has collaborated with esteemed colleagues, including Shlomo Nedvetzki and Itshak Golan. These partnerships have fostered a collaborative environment that has led to innovative breakthroughs in his field.

Conclusion

David Naor's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the industry. His work on CD44 polypeptides showcases the potential for innovative treatments in inflammatory diseases.